ArticleJournal of translational medicine2025
GSDME-N-induced mitochondrial neurotoxicity in early neurodegeneration was suppressed by nicotine via enhancing autophagic flux.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- PTEN-L inhibits mitophagy and GSDME-dependent pyroptosis via Parkin dephosphorylation.EMBO reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundNeurodegeneration is a chronic, progressive process initiated by early neurite retraction, a pathological hallmark preceding neuronal death in neurodegenerative disorders such as Parkinson’s disease (PD). Cleavage of gasdermin E (GSDME) releases its N-terminal domain (GSDME-N), which has been shown to mediate mitochondrial dysfunction and the onset of neurodegeneration. However, the therapeutic potential of targeting GSDME-N for early intervention in PD, and whether nicotine, a tobacco component with neuroprotective properties, acts through GSDME modulation remain unexplored.
methodsThe SH-SY5Y cells, primary neurons and C57BL mice were treated with rotenone to model neurodegeneration in PD. Mitochondrial accumulation of GSDME-N and activation of autophagy were assessed via immunoblotting and immunostaining. Mitochondrial membrane potential was evaluated using JC-1 and TMRM fluorescent dyes, while mitochondrial reactive oxygen species were detected with MitoSOX™ Red superoxide indicator. For morphological analysis, immunofluorescence staining was performed using antibodies against microtubule-associated protein 2 (MAP2) to visualize neurites, along with MitoTracker to label mitochondria within neurites. In vivo, C57BL/6 mice were administered rotenone and provided with nicotine supplementation in their drinking water. Motor function was assessed using rotarod, hanging wire and pole tests. Tyrosine hydroxylase (TH)-positive neurons and fibers were detected using immunohistochemistry.
resultsWe demonstrated that GSDME-N accumulation on mitochondria during early neurodegeneration was suppressed by nicotine, thereby maintaining mitochondrial homeostasis and preventing neurite retraction. Mechanistically, nicotine activated autophagic pathway to promote GSDME-N clearance, which maintained mitochondrial membrane potential, reduced reactive oxygen species (ROS) production, and specifically rescued mitochondrial function. This protective mechanism significantly attenuated early pathological changes, including neurite retraction and loss. In a rotenone-induced PD model, nicotine treatment effectively reduced GSDME-N accumulation and decelerated neurodegenerative progression.
conclusionsThese findings reveal the critical role of GSDME-N in early-stage mitochondrial damage in PD and propose a novel therapeutic strategy targeting the nicotine-autophagy axis to counteract GSDME-N-mediated neurodegeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.